Update shared on 21 Nov 2025
Fair value Increased 14%Analysts have raised their price target for Vivos Therapeutics from $5.10 to $5.83 per share. They cited improved revenue growth projections and modest adjustments to future profitability assumptions.
What's in the News
- Vivos Therapeutics announced a delay in filing their next 10-Q with the SEC, missing the required deadline (Key Developments).
- The company held its annual general meeting, and declared voting results indicate the withdrawal of the investor activism campaign by SP Manager LLC (Key Developments).
- Baker Tilly US, LLP was approved as the new independent registered public accounting firm for the fiscal year ending December 31, 2025, replacing Moss Adams LLP (Key Developments).
- New clinical data shows Vivos' FDA-cleared DNA device provides significant relief for children with ADHD and OSA, offering a non-surgical and non-pharmaceutical alternative for pediatric OSA (Key Developments).
- Peer-reviewed published data confirm the safety and efficacy of the Vivos DNA appliance in treating pediatric OSA, with major reductions in severity and airway improvements reported in a multicenter clinical trial (Key Developments).
Valuation Changes
- Consensus Analyst Price Target has increased from $5.10 to $5.83 per share, reflecting improved expectations.
- Discount Rate has risen slightly, moving from 6.78% to 6.98%.
- Revenue Growth projection has increased significantly, from 39.4% to 56.5%.
- Net Profit Margin is marginally lower, shifting from 5.39% to 5.24%.
- Future P/E ratio has decreased, moving from 26.6x to 22.2x. This suggests improved valuation efficiency.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.